Antidepressants have helped millions through the black days of depression, but their usefulness has always been limited, as a significant number of patients either experience serious treatment related side-effects or, for them, the treatment simply doesn’t work.
Andrew Gardiner is a man on a mission to drive up antidepressant efficacy. Through his company Syntropharma, Gardiner has developed a transdermal MAOI (Monoamine Oxidase Inhibitor) patch, a delivery system that aims to significantly reduce potential side-effects and improve the lives of many millions suffering from depression and other mood disorders.
Oral MAOI treatments are very effective, but rarely used today owing to their health risks when passing through the digestive system. Syntropharma’s MAOI is not a tablet, the drug is delivered transdermally via a skin patch, meaning the treatment avoids the potentially harmful effects of oral dosing, whilst maintaining the undoubted efficacy of the tablets.
Andrew Gardiner notes: “Physicians now have a new option to treat patients with depression; the product has recently been granted a license in Argentina and with other submissions for key markets in the EU and the USA also under way, we hope the treatment can be used on an international scale in the near future.”
Gardiner has spent more than 30 years in the pharmaceutical and life sciences market, with the last decade dedicated to building Syntropharma, working to transform the delivery of existing medications for a range of common conditions to improve safety, efficacy and compliance.
“One out of three people are not helped at all by their antidepressant medication, showing a clear need for new therapies and strategies. Our product will help many patients suffering from this all too common affliction,” he said.
Syntropharma specializes in the development of transdermal patch delivery of medicines for central nervous system conditions, such as depression. Transdermal drug delivery has been shown to reduce side-effects and increase compliance, with patches for nicotine withdrawal and hormone replacement therapy helping to drive overall acceptance of patches as treatment options. The global market for transdermal medication has grown from £8.2 billion in 2005 to £19.5 billion in 2015.
Syntropharma is using equity crowdfunding platform SyndicateRoom to raise £400,000 to fund the manufacture of stock to satisfy demand, and has already reached more than 60% of that total. To find out more, click here.